![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2021
Though we had hoped to meet in person this fall, the pandemic has kept us on our toes—and in front of our screens.
October 19, 2021
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 19, 2021
In September, the field of immunotherapy lost one of its pioneers
October 19, 2021
In September, the field of oncology lost a worldwide ovarian therapeutics leader and unparalleled mentor to generations
October 19, 2021
This phase II randomized controlled trial is comparing the effectiveness of two different approaches to help recently diagnosed patients with cancer become smoke-free
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
September 30, 2021
This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
August 17, 2021
A Standing Main Member of ECOG-ACRIN since 1972
July 7, 2021
This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer